{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 49,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "key_takeaways",
  "function": "quantify_opportunity",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/29",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.51,
        "y": 0.71
      },
      "kind": "callout",
      "text": "Ultomiris offers continuous disease control with minimal doses per year, compared to other branded medicines",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f54b4cc-080b-4981-80f8-1b38fff43a5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.35,
        "x": 0.06,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Branded market expansion chart",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35dd5481-0b14-41f0-8353-781fe63050d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.53,
        "y": 0.29
      },
      "kind": "chart",
      "text": "1/3 of Ultomiris utilization from complement naïve patients",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ce8c54e-d7cc-4e53-934b-020f89fe1d74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.8,
        "x": 0.036,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "1. Ultomiris addressable population c.30k patients in the US compared to 8-10k for Soliris, due to requirement to fail two prior IST regimens in Soliris Phase III REGAIN trial. gMG = generalised myasthenia gravis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09f67e1d-ad3b-49ff-9794-5ac48a33ff6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.036,
        "y": 0.135
      },
      "kind": "title",
      "text": "3x addressable patient population, new market entrants expand branded market",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91855a94-b030-4326-9d6c-f1c929e5641f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.036,
        "y": 0.068
      },
      "kind": "title",
      "text": "Ultomiris first step to expand reach in gMG",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0588601-7bed-47c4-b428-c9d219f71947",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 20,
      "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142",
      "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space",
      "position": 2,
      "objective": "What are the key opportunities for AstraZeneca's Rare Disease division",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}